시장보고서
상품코드
1098619

척수성 근위축증 시장 규모, 점유율, 전망, 기회(2022-2030년) : 종류, 치료법, 연령층, 투여 경로, 유통 경로, 지역별

Spinal Muscular Atrophy Market, by Type, by Treatment, by Age Group, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

발행일: | 리서치사: Coherent Market Insights | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

주요 기업에 의한 제품 출시 증가가 예측기간 중 척수성 근위축증 시장 성장을 촉진할 것으로 예상됩니다. 또한 주요 기업에 의한 제휴·협력 등의 무기적 전략 채용 증가도 예측기간 중 시장 성장 원동력이 될 것으로 예상됩니다.

세계의 척수성 근위축증(Spinal Muscular Atrophy) 시장을 조사했으며, 시장 정의와 개요, 시장 성장에 대한 각종 영향요인 분석, 규제 상황, 기술 동향, 시장 규모 추정과 예측, 각종 부문·지역/주요 국가별 내역, 경쟁 환경, 주요 기업 개요 등을 정리했습니다.

목차

제1장 조사 목적과 가정

제2장 시장 개요

제3장 시장 역학, 규제, 동향 분석

  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
  • 영향 분석
  • 시장 동향
  • 인수·제휴
  • 기술 진보
  • 규제 시나리오
  • PEST 분석
  • 제품 발매

제4장 세계의 척수성 근위축증 시장 : COVID-19의 영향

  • 전체적인 영향
  • 정부 정책
  • COVID-19 : 시장에 대한 영향

제5장 세계의 척수성 근위축증 시장 : 종류별

  • 개요
  • 타입 I
  • 타입 II
  • 타입 III
  • 타입 IV

제6장 세계의 척수성 근위축증 시장 : 치료별

  • 개요
  • 유전자 치료
  • 질환 조절약

제7장 세계의 척수성 근위축증 시장 : 연령별

  • 개요
  • 소아
  • 성인

제8장 세계의 척수성 근위축증 시장 : 투여 경로별

  • 개요
  • 경구
  • 주사

제9장 세계의 척수성 근위축증 시장 : 유통 경로별

  • 개요
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제10장 세계의 척수성 근위축증 시장 : 지역별

  • 북미
  • 라틴아메리카
  • 유럽
  • 아시아태평양
  • 중동
  • 아프리카

제11장 경쟁 상황

  • Biogen
  • CYTOKINETICS
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • PTC Therapeutics, Inc.
  • Novartis AG
  • Ionis Pharmaceuticals
  • Chugai Pharmaceutical Co., Ltd.
  • NMD PHARMA A/S
  • Astellas Pharma Inc.

제12장 섹션

KSM 22.07.15

Spinal muscular atrophy (SMA) is a genetic disease that affects the peripheral nervous system, central nervous system, and voluntary muscle movement (skeletal muscle). SMA is muscular since it primarily affects muscles, which do not receive impulses from the nerve cells. Atrophy is the medical term for shrinking, which is what muscles do when they are not stimulated by nerve cells. SMA is a motor neuron disease that includes the loss of nerve cells termed motor neurons in the spinal cord. It mostly affects infants and children but can also develop in adults. An individual with SMA inherits two copies of a faulty (mutated) or missing survival motor neuron 1 (SMN1) gene.

Market Dynamics

The increasing product launches by the key players in the market are expected to drive the market growth over the forecast period. For instance, in August 2021, Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan, announced that it had launched Evrysdi Dry Syrup 60 mg (generic name: risdiplam) for the treatment of spinal muscular atrophy (SMA).

Moreover, the increasing adoption of inorganic strategies such as partnerships and collaborations by the key players is expected to drive the market growth over the forecast period. For instance, in March 2021, the Spinal Muscular Atrophy Foundation, the leading funder of SMA research worldwide, and PTC Therapeutics, Inc., a U.S. based pharmaceutical company, entered into a new collaboration focused on developing new treatments and regenerative medicine to further advance scientific research in SMA and other neuromuscular disorders.

Key features of the study:

  • This report provides in-depth analysis of the global spinal muscular atrophy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global spinal muscular atrophy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Biogen, CYTOKINETICS, Hoffmann-La Roche Ltd, Genentech, Inc., PTC Therapeutics, Inc., Novartis AG, Ionis Pharmaceuticals, Chugai Pharmaceutical Co., Ltd., NMD PHARMA A/S, and Astellas Pharma Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global spinal muscular atrophy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global spinal muscular atrophy market

Detailed Segmentation:

  • Global Spinal Muscular Atrophy Market, By Type:
  • Type I
  • Type II
  • Type III
  • Type IV
  • Global Spinal Muscular Atrophy Market, By Treatment:
  • Gene Therapy
  • Disease-modifying drugs
  • Global Spinal Muscular Atrophy Market, By Age Group:
  • Infant
  • Adult
  • Global Spinal Muscular Atrophy Market, By Route of Administration:
  • Oral
  • Injectables
  • Global Spinal Muscular Atrophy Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Spinal Muscular Atrophy Market, By Region:
  • North America
    • By Type
    • Type I
    • Type II
    • Type III
    • Type IV
    • By Treatment
    • Gene Therapy
    • Disease-modifying drugs
    • By Age Group
    • Infant
    • Adult
    • By Route of Administration
    • Oral
    • Injectables
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country
    • U.S.
    • Canada
  • Latin America
    • By Type
    • Type I
    • Type II
    • Type III
    • Type IV
    • By Treatment
    • Gene Therapy
    • Disease-modifying drugs
    • By Age Group
    • Infant
    • Adult
    • By Route of Administration
    • Oral
    • Injectables
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • By Type
    • Type I
    • Type II
    • Type III
    • Type IV
    • By Treatment
    • Gene Therapy
    • Disease-modifying drugs
    • By Age Group
    • Infant
    • Adult
    • By Route of Administration
    • Oral
    • Injectables
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • By Type
    • Type I
    • Type II
    • Type III
    • Type IV
    • By Treatment
    • Gene Therapy
    • Disease-modifying drugs
    • By Age Group
    • Infant
    • Adult
    • By Route of Administration
    • Oral
    • Injectables
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • By Type
    • Type I
    • Type II
    • Type III
    • Type IV
    • By Treatment
    • Gene Therapy
    • Disease-modifying drugs
    • By Age Group
    • Infant
    • Adult
    • By Route of Administration
    • Oral
    • Injectables
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Country
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • By Type
    • Type I
    • Type II
    • Type III
    • Type IV
    • By Treatment
    • Gene Therapy
    • Disease-modifying drugs
    • By Age Group
    • Infant
    • Adult
    • By Route of Administration
    • Oral
    • Injectables
    • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • By Region/Country
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
  • Biogen
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • CYTOKINETICS
  • Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • PTC Therapeutics, Inc.
  • Novartis AG
  • Ionis Pharmaceuticals
  • Chugai Pharmaceutical Co., Ltd.
  • NMD PHARMA A/S
  • Astellas Pharma Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Type
    • Market Snapshot, By Treatment
    • Market Snapshot, By Age
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Acquisitions and Partnerships Scenario
  • Technological Advancements
  • Regulatory Scenario
  • PEST Analysis
  • Product Launches

4. Global Spinal Muscular Atrophy Market- Impact of Coronavirus (Covid-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the market

5. Global Spinal Muscular Atrophy Market, By Type, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Type I
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Type II
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Type III
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Type IV
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Spinal Muscular Atrophy Market, By Treatment, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Gene Therapy
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Disease-modifying drugs
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Spinal Muscular Atrophy Market, By Age, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Infant
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Adult
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Spinal Muscular Atrophy Market, By Route of Administration, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Oral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Injectables
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

9. Global Spinal Muscular Atrophy Market, By Distribution Channel, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

10. Global Spinal Muscular Atrophy Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
    • U.S.
    • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
    • UK
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Age, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

11. Competitive Landscape

  • Biogen
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • CYTOKINETICS
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • F. Hoffmann-La Roche Ltd
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Genentech, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • PTC Therapeutics, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Ionis Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Chugai Pharmaceutical Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • NMD PHARMA A/S
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Astellas Pharma Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

12. Section

  • Research Methodology
  • About Us
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제